2023
Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 Global Rheumatology Alliance Registry
Yazdany J, Ware A, Wallace Z, Bhana S, Grainger R, Hachulla E, Richez C, Cacoub P, Hausmann J, Liew J, Sirotich E, Jacobsohn L, Strangfeld A, Mateus E, Hyrich K, Gossec L, Carmona L, Lawson‐Tovey S, Kearsley‐Fleet L, Schaefer M, Ribeiro S, Al‐Emadi S, Hasseli R, Müller‐Ladner U, Specker C, Schulze‐Koops H, Bernardes M, Fraga V, Rodrigues A, Sparks J, Ljung L, Di Giuseppe D, Tidblad L, Wise L, Duarte‐García A, Ugarte‐Gil M, Colunga‐Pedraza I, Martínez‐Martínez M, Alpizar‐Rodriguez D, Xavier R, Isnardi C, Pera M, Pons‐Estel G, Izadi Z, Gianfrancesco M, Carrara G, Scirè C, Zanetti A, Machado P. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 Global Rheumatology Alliance Registry. Arthritis Care & Research 2023, 76: 274-287. PMID: 37643903, DOI: 10.1002/acr.25220.Peer-Reviewed Original ResearchB-cell depleting therapySevere COVID-19Rheumatic diseasesCOVID-19 outcomesUnvaccinated peopleRisk factorsWorse outcomesCOVID-19Severe COVID-19 outcomesTumor necrosis factor inhibitorsHigh disease activityNecrosis factor inhibitorsConnective tissue diseaseCOVID-19 severityCOVID-19 vaccineThird of individualsLogistic regression modelsCOVID-19 diagnosisOrdinal logistic regression modelsLow HDI regionsMore comorbiditiesUnvaccinated patientsDisease activityUnvaccinated individualsFactor inhibitorsCharacteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Machado P, Schäfer M, Mahil S, Liew J, Gossec L, Dand N, Pfeil A, Strangfeld A, Regierer A, Fautrel B, Alonso C, Saad C, Griffiths C, Lomater C, Miceli-Richard C, Wendling D, Rodriguez D, Wiek D, Mateus E, Sirotich E, Soriano E, Ribeiro F, Omura F, Martins F, Santos H, Dau J, Barker J, Hausmann J, Hyrich K, Gensler L, Silva L, Jacobsohn L, Carmona L, Pinheiro M, Zelaya M, de los Ángeles Severina M, Yates M, Dubreuil M, Gore-Massy M, Romeo N, Haroon N, Sufka P, Grainger R, Hasseli R, Lawson-Tovey S, Bhana S, Pham T, Olofsson T, Bautista-Molano W, Wallace Z, Yiu Z, Yazdany J, Robinson P, Smith C. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. Annals Of The Rheumatic Diseases 2023, 82: 698-709. PMID: 36787993, PMCID: PMC10176347, DOI: 10.1136/ard-2022-223499.Peer-Reviewed Original ResearchConceptsSevere COVID-19High disease activityPandemic time periodDisease activityPsoriatic arthritisMale sexAxial spondyloarthritisCOVID-19Multivariable ordinal logistic regressionPoor COVID-19 outcomesOlder ageFuture respiratory pandemicsCOVID-19 severityCOVID-19 outcomesComorbidity burdenGlucocorticoid intakeGlucocorticoid useCancer comorbidityClinical characteristicsCOVID-19 waveRisk stratificationOrdinal logistic regressionReduced oddsSeverity ScaleRespiratory pandemic
2022
Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Yeoh S, Gianfrancesco M, Lawson-Tovey S, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Schäfer M, Richez C, Hachulla E, Holmqvist M, Scirè C, Lorenz H, Voll R, Hasseli R, Jayatilleke A, Hsu T, D’Silva K, Pimentel-Quiroz V, del Mercado M, Shinjo S, dos Reis Neto E, da Rocha L, de Oliveira e Silva Montandon A, Pons-Estel G, Ornella S, Exeni M, Velozo E, Jordan P, Sirotich E, Hausmann J, Liew J, Jacobsohn L, Gore-Massy M, Sufka P, Grainger R, Bhana S, Wallace Z, Robinson P, Yazdany J, Machado P. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. RMD Open 2022, 8: e002508. PMID: 36100295, PMCID: PMC9471207, DOI: 10.1136/rmdopen-2022-002508.Peer-Reviewed Original ResearchConceptsIdiopathic inflammatory myopathiesSevere COVID-19Prednisolone-equivalent doseHigh disease activityDisease activityInflammatory myopathiesMale sexSevere outcomesCOVID-19Multivariable ordinal logistic regressionOlder ageHigher comorbidity burdenLarge registry dataCOVID-19 diagnosisComorbidity burdenRituximab exposureClinical characteristicsRisk stratificationOrdinal logistic regressionRegistry dataHospitalisationSeverity ScaleDemographic dataLogistic regressionPatientsOP0252 FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY
Yeoh S, Gianfrancesco M, Lawson-Tovey S, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Schaefer M, Richez C, Hachulla E, Holmqvist M, Scirè C, Hasseli R, Jayatilleke A, Hsu T, D’Silva K, Pimentel-Quiroz V, Vasquez del Mercado M, Katsuyuki Shinjo S, Reis Neto E, Rocha L, Montandon A, Jordan P, Sirotich E, Hausmann J, Liew J, Jacobsohn L, Gore-Massy M, Sufka P, Grainger R, Bhana S, Wallace Z, Robinson P, Yazdany J, Machado P. OP0252 FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY. Annals Of The Rheumatic Diseases 2022, 81: 165-166. DOI: 10.1136/annrheumdis-2022-eular.3235.Peer-Reviewed Original ResearchIdiopathic inflammatory myopathiesIdiopathic inflammatory myopathy patientsHigh disease activityDisease activityOdds ratioGrant/research supportAstra ZenecaInflammatory myopathiesSynthetic DMARDsCOVID-19 severity scaleCOVID-19 outcomesBristol-Myers SquibbMultivariate logistic regression analysis of factorsBoehringer IngelheimDisease-modifying anti-rheumatic drugsIIM casesSanofi GenzymeAssociated with worse outcomesFactors associated with severe COVID-19 outcomesMultivariate logistic regression analysisExposure to rituximabOutcomes of patientsConventional synthetic DMARDsAnti-rheumatic drugsLogistic regression analysis of factorsOP0249 CHARACTERISTICS ASSOCIATED WITH POOR COVID-19 OUTCOMES IN PEOPLE WITH PSORIASIS AND SPONDYLOARTHRITIS: DATA FROM THE COVID-19 PsoProtect AND GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRIES
Machado P, Schaefer M, Mahil S, Dand N, Gianfrancesco M, Lawson-Tovey S, Yiu Z, Yates M, Hyrich K, Gossec L, Carmona L, Mateus E, Wiek D, Bhana S, Gore-Massy M, Grainger R, Hausmann J, Sufka P, Sirotich E, Wallace Z, Olofsson T, Lomater C, Romeo N, Wendling D, Pham T, Miceli Richard C, Fautrel B, Silva L, Santos H, Martins F, Hasseli R, Pfeil A, Regierer A, Isnardi C, Soriano E, Quintana R, Omura F, Machado Ribeiro F, Pinheiro M, Bautista-Molano W, Alpizar-Rodriguez D, Saad C, Dubreuil M, Haroon N, Gensler L, Dau J, Jacobsohn L, Liew J, Strangfeld A, Barker J, Griffiths C, Robinson P, Yazdany J, Smith C. OP0249 CHARACTERISTICS ASSOCIATED WITH POOR COVID-19 OUTCOMES IN PEOPLE WITH PSORIASIS AND SPONDYLOARTHRITIS: DATA FROM THE COVID-19 PsoProtect AND GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRIES. Annals Of The Rheumatic Diseases 2022, 81: 163-164. DOI: 10.1136/annrheumdis-2022-eular.1753.Peer-Reviewed Original ResearchIL-23/IL-12High disease activitySevere COVID-19 outcomesDisease activityAssociated with severe COVID-19 outcomesCOVID-19 outcomesGlobal Rheumatology AllianceMale sexPooled analysis of dataFactors associated with severe COVID-19 outcomesDiagnosis of PsOPsoriasis patient registriesIL-17 inhibitorsAnti-rheumatic drugsOlder agePhysician-reported disease activityChronic kidney diseaseMultivariate ordinal logistic regression modelGC intakeIL-17iCOVID-19 severityActive diseaseSpecificity of patientsCOVID-19 Global Rheumatology AllianceAxial spondyloarthritis
2021
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Strangfeld A, Schäfer M, Gianfrancesco M, Lawson-Tovey S, Liew J, Ljung L, Mateus E, Richez C, Santos M, Schmajuk G, Scirè C, Sirotich E, Sparks J, Sufka P, Thomas T, Trupin L, Wallace Z, Al-Adely S, Bachiller-Corral J, Bhana S, Cacoub P, Carmona L, Costello R, Costello W, Gossec L, Grainger R, Hachulla E, Hasseli R, Hausmann J, Hyrich K, Izadi Z, Jacobsohn L, Katz P, Kearsley-Fleet L, Robinson P, Yazdany J, Machado P, Dahou B, Pinheiro M, Ribeiro F, Chassin-Trubert A, Ibáñez S, Dong L, Cajas L, Hamoud H, Avouac J, Belin V, Borie R, Chazerain P, Chevalier X, Claudepierre P, Clavel G, Colette-Cedoz M, Combe B, Constant E, Costedoat-Chalumeau N, Desmurs M, Devauchelle-Pensec V, Devaux M, Dhote R, Dieudonné Y, Domont F, Duret P, Ebbo M, Ebstein E, Mahou S, Fautrel B, Felten R, Flipo R, Foltz V, Froissart A, Galland J, Gaud-Listrat V, Georgin-Lavialle S, Giraud-Morelet A, Quitrec J, Goupille P, Govindaraju-Audouard S, Grados F, Guillaume-Czitrom S, Hermet M, Hittinger-Roux A, Hudry C, Kone-Paut I, La Batide Alanore S, Lafforgue P, Lahalle S, Lambrecht I, Langlois V, Larbre J, Ledoult E, Leroux C, Liote F, Maria A, Marotte H, Mekinian A, Melki I, Messer L, Michel C, Morel G, Morel J, Paris-Havard M, Pertuiset E, Pham T, Renard M, Revuz S, Rivière S, Rousselin C, Roux C, Rouzaud D, Sellam J, Seror R, Servettaz A, Sobanski V, Sordet C, Spielmann L, Tieulié N, Tison A, Trijau S, Virone A, Warzocha U, Wendling D, Albach F, Aries P, Decker E, Hartmann U, Henes J, Hoyer B, Krause A, Krüger K, Lorenz H, Müller-Ladner U, Pfeil A, Regierer A, Richter J, Rihl M, Schmeiser T, Schulze-Koops H, Specker C, Voll R, Werner S, Melgar G, Vojdanian, Andreoli L, Bartoloni-Bocci E, Benucci M, Campanaro F, Caprioli M, Carboni D, Carrara G, Cipolletta E, Crotti C, Dallagiacoma G, Faggioli P, Foti R, Franceschini F, Fredi M, Guidelli G, Iannone F, Landolfi G, Lomater C, Nalli C, Parisi S, Quartuccio L, Raffeiner B, Reggia R, Riva M, Romeo N, Rotondo C, Silvagni E, Sinigaglia L, Tinazzi I, Zanetti A, Zanframundo G, Abutiban F, Alpízar-Rodríguez D, Rull-Gabayet M, Irazoque F, Jimenez X, Martín-Nares E, Castillo-Ortiz A, Rodriguez-Reyna T, Rosete D, Zamora-Tehozol E, Vega-Morales D, Zaueta-Montiel B, Al-Adhoubi N, Salim B, Giraldo E, Salinas A, Ugarte-Gil M, Almeida D, Bernardes M, Machado R, Rato M, Al-Emadi S, Conway R, Flood R, Alegre-Sancho J, Coro M, de la Torre-Rubio N, Esteban J, del Martin M, Puerta J, Back J, Dastmalchi M, Dupré B, Grenholm E, Hensvold A, Knight A, Akar S, Icacan O, Chadwick L, Devine K, Dunt S, Fusi L, Jones C, Macphie E, Nikiphorou E, O'Kane D, O'Reilly S, Patel S, Salerno R, Thornton L, Tyler J, Vandevelde C, Warner E, Yeoh S, Baig S, Bajwa H, Ban B, Berglund V, Calabrese C, D'Silva K, Dahle A, Dao K, Daver N, Davis W, Dorman W, Fatemeh E, Fields T, Hargrove J, Harvey M, Hilton M, Hsu T, Izadi Z, Jayatilleke A, Karp D, Kepecs G, Kramer N, Lamore C, Lebedoff N, Leonard S, Mody S, Morgan J, Pfeifer E, Quiceno G, Quinet R, Rosenstein E, Ruderman E, Scopelitis E, Serling-Boyd N, Siddique F, Skemp A, Sparks J, Todd D, Toribio K, Wallwork R, Webb-Detiege T, White D, Wilson J, Winter M, Wise L, Wolff A, Young K, Zakem J, Zell J, Zimmerman K. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals Of The Rheumatic Diseases 2021, 80: 930-942. PMID: 33504483, PMCID: PMC7843211, DOI: 10.1136/annrheumdis-2020-219498.Peer-Reviewed Original ResearchConceptsDisease-modifying anti-rheumatic drugsCOVID-19-related deathsHigh disease activityRheumatic diseasesDisease activityHigher oddsBiological disease-modifying anti-rheumatic drugsMultivariable logistic regression modelRegistry of adultsRheumatic disease diagnosisAnti-rheumatic drugsChronic lung diseaseDisease-specific factorsAdequate disease controlLogistic regression modelsGlucocorticoid dosageMethotrexate monotherapyPrimary outcomeSmoking statusMale sexLung diseaseCardiovascular diseaseIndependent factorsDisease categoriesDisease control